Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostate Cancer Metastatic × 90 days × Clear all

Phase

Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 101 Breast Neoplasms 99 Prostatic Neoplasms 49 Neoplasms 47 Multiple Myeloma 44 Lung Neoplasms 32 Parkinson Disease 4, Autosomal Dominant Lewy Body 30 Neoplasm Metastasis 28 Colorectal Neoplasms 28 Ovarian Neoplasms 27 Stomach Neoplasms 24 Leukemia, Myeloid, Acute 22 Urinary Bladder Neoplasms 21 Myasthenia Gravis 21 Lymphoma, Follicular 20 Leukemia, Lymphocytic, Chronic, B-Cell 20 Carcinoma, Hepatocellular 20 Squamous Cell Carcinoma of Head and Neck 19 Recurrence 18 Melanoma 18 Small Cell Lung Carcinoma 17 Lymphoma, Large B-Cell, Diffuse 17 Brain Neoplasms 17 Endometrial Neoplasms 16 Carcinoma, Renal Cell 16 Colonic Neoplasms 15 Lymphoma 14 Carcinoma 13 Adenocarcinoma 13 Triple Negative Breast Neoplasms 12

Interventions

fludrocortisone acetate 1 enzalutamide 1 Prednisone 1 Hydrocortisone 1 Dexamethasone 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06136624 2026-03-11

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡